Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 484 participants.
Also called NCT06096337
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 484 participants
- Sponsor
- Registry
-
NCT06096337
-
- Other papers using this trial's data
- Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Australia, Austria, Belgium, Canada, Croatia, France, Germany, Hong Kong SAR China, Italy, Singapore, Spain, Taiwan
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06096337. Randomized; no masking; primary purpose treatment. Start 2023-12-28 (actual); primary completion 2026-02-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
- Acronym
- AVANT GUARD
- Condition
- Persistent Atrial Fibrillation
- Intervention (Device)
- FARAPULSE™ Pulsed Field Ablation (PFA) System
- Intervention (Drug)
- Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct06096337- Content hash
6b30c2d668c651ad77aa46cb15ddffe8fab8fd7bd61d075bdb13223ba110c9a6